Foresite Capital is an American venture capital and growth equity firm headquartered in San Francisco.[1][2] As of March 2021, the company had raised five funds: Foresite Capital Fund I, II, III, IV and V.[1][3]
| Company type | Private |
|---|---|
| Industry | Venture capital, growth equity |
| Founded | 2011 |
| Founder | Jim Tananbaum, CEO |
| Headquarters | , |
Area served | Worldwide |
| Website | www |
History edit
Foresite Capital was founded in 2011 by Jim Tananbaum.[4][5][6] Foresite Capital raised its $100 million Fund I in 2013.[7][8][6] In 2014, Foresite Capital closed Foresite Capital Fund II, a $300 million fund.[9] Foresite Capital Fund III, a $450 million fund, was closed in July 2015.[9] Foresite Capital Fund IV, a $668 million fund, closed in March 2018.[10] Foresite Capital Fund V, a $969 million fund, was closed in February 2021.[11]
Investments edit
Foresite Capital funded 10x Genomics since its Series A round in November 2013 and led its Series B round in January 2015, as well as its Series C round in March 2016.[12][13] Foresite Capital has invested in companies such as Acceleron Pharma, Aimmune, ALX Oncology, Aerie Pharmaceuticals,[14] Ascendis, Blueprint Medicines, Color Genomics, Cue Health, Cytokinetics, DNAnexus,[citation needed] Editas Medicine,[15] Eikon Therapeutics, Epizyme,[1] Evonetix, Intarcia Therapeutics,[16][17] Inscripta,[18] Immunomedics,[19][20] Intellia Therapeutics,[citation needed] Juno Therapeutics,[21] Karyopharm, Keryx, Kura Oncology, Keros Therapeutics, Maze Therapeutics, MyoKardia, MyOme, Natera,[19] Nurix, Olema Oncology, Orexigen,[22] Pacific Biosciences,[23] Peloton Therapeutics, Pharvaris, MindStrong Health, Quantum-SI, Relay Therapeutics,[24] Insitro,[25] HealthVerity, Turning Point Therapeutics, Element Biosciences,[26] Portola Pharmaceuticals, Universal American, Xencor, and WaveTech, in addition to 10x Genomics.[27]
Leadership edit
Foresite Capital is led by Midas List honoree Jim Tananbaum along with managing directors Matt Buten, Alisa Mall,[28] Dorothy Margolskee, Michael Rome, Dennis Ryan, and Vikram Bajaj.[29][30]
References edit
- ^ a b c David Holley (29 July 2015). "Foresite Capital Keeps Late-Stage Healthcare Focus With $450M Third Fund". Xconomy. Retrieved 20 May 2017.
- ^ Brian Gormley (31 January 2013). "Growth-Equity Firm Foresite Capital Raises $100M for Debut Health-Care Fund". Wall Street Journal. Retrieved 20 May 2017.
- ^ "Foresite Capital launchew new venture capital fund worth $668 million". Biospace. Retrieved 21 June 2019.
- ^ Damian Garde (29 July 2015). "Foresite Capital reloads with a $450M biotech venture fund". Fierce Biotech. Retrieved 20 May 2017.
- ^ "Foresite Capital raises $100M to invest in late-stage healthcare companies". San Francisco Business Times. 31 January 2013. Retrieved 20 May 2017.
- ^ a b Eric Blattberg (1 April 2014). "Health care venture firm Foresite Capital closes $300M fund". Venture Beat. Retrieved 20 May 2017.
- ^ Ben Fidler (6 November 2013). "Karyopharm Prices Upsized IPO at $16 Per Share, Begins Trading Today". Xconomy. Retrieved 20 May 2017.
- ^ Luke Timmerman (31 January 2013). "Foresite Capital Closes $100M Fund for Late-Stage Biotechs". Xconomy. Retrieved 20 May 2017.
- ^ a b Damian Gards (1 April 2014). "Foresite banks $300M to bet on late-stage biotechs". Fierce Biotech. Retrieved 20 May 2017.
- ^ "Venture fund Foresite Capital raises largest-ever $668m fund". Mass Device. 4 May 2018. Retrieved 19 June 2019.
- ^ "Foresite Capital raises $969 million fund to invest in healthcare startups across all stages of growth". TechCrunch. Retrieved 2021-03-16.
- ^ Nick Paul Taylor (21 March 2016). "10X Genomics scoops another $55M to fuel commercialization of long-read tech". Fierce Biotech. Retrieved 20 May 2017.
- ^ Alex Lash (12 January 2015). "10X Genomics Emerges With $80M and Toaster-Sized Sequencer Upgrade". Xconomy. Retrieved 20 May 2017.
- ^ Ed Lin (14 October 2016). "Aerie Stock Hits Record High, Holder Sells $2 Million". Barrons. Retrieved 20 May 2017.
- ^ "Foresite Capital - Massinvestor Venture Capital and Private Equity Database". massinvestordatabase.com. Retrieved 2019-02-27.
- ^ Dan Primack (15 September 2016). "Diabetes 'Unicorn' Raises Final VC Round Before IPO". Fortune. Retrieved 20 May 2017.
- ^ "Here's who stands to gain from Intarcia's success with a type 2 diabetes pump". Boston Business Journal. 2 October 2014. Retrieved 20 May 2017.
- ^ "Muse Bio Closes $23M Series B Financing Round". Genome Web. Retrieved 20 May 2017.
- ^ a b "FORESITE CAPITAL MANAGEMENT III, LLC Institutional Portfolio". NASDAQ.com. Retrieved 2019-05-02.
- ^ "Intarcia Therapeutics Venture Capital and Private Equity Financings". www.vcnewsdaily.com. Retrieved 2019-02-27.
- ^ "Foresite Capital reloads with a $450M biotech venture fund". FierceBiotech. Retrieved 2019-05-02.
- ^ "Xconomy: Foresite Capital Reloads With New $300M Late-Stage Biotech Fund". Xconomy. 2014-04-01. Retrieved 2019-05-14.
- ^ Timmerman, Luke. "Stealthy 10X Genomics Raises $55.5M To Beef Up DNA Sequencing". Forbes. Retrieved 2019-05-14.
- ^ "Relay Therapeutics hits VC jackpot with $400M series C round for protein-motion drug discovery". Med City News. 20 December 2018. Retrieved 19 June 2019.
- ^ "Backed by big-name VCs, this startup is turning machine learning on drug discovery". The Business Journals. Retrieved 19 June 2019.
- ^ "Element Biosciences Lands $15M to Develop New Genetic Analysis Tools". Xconomy. Retrieved 21 June 2019.
- ^ "Foresite Capital Management Iv, Llc - Latest 13F Holdings - Fintel.io". fintel.io. Retrieved 2019-05-14.
- ^ "Heir Apparent at Carnegie Corp. Exits for Biotech Venture Firm". Institutional Investor. 14 October 2020. Retrieved 18 December 2020.
- ^ "A life sciences firm run by a top VC and a cofounder of Alphabet's life sciences arm, just raised its biggest fund yet". TechCrunch. 5 May 2018. Retrieved 19 June 2019.
- ^ "Nine VCs who matter but you never read about". Knect365. Retrieved 19 June 2019.